Many Ophthotech Corporation(OPHT) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Ophthotech Corp was Downgraded by Morgan Stanley to Equal-Weight on Dec 13, 2016. Ophthotech Corp was Upgraded by Goldman to Neutral on Dec 13, 2016. Ophthotech Corp was Downgraded by Gabelli & Co to Hold on Dec 13, 2016. Ophthotech Corp was Downgraded by Leerink Partners to Mkt Perform on Dec 12, 2016. Ophthotech Corp was Downgraded by Chardan Capital Markets on Dec 12, 2016 to Neutral, Lowers Price Target to $ 15 from a previous price target of $200 .
Company has reported several Insider transactions to the SEC, on Jan 23, 2017, Axel Bolte (director) sold 6,000 shares at 4.83 per share price.On Jan 6, 2017, Barbara A Wood (SVP,General Counsel,Secretary) sold 589 shares at 4.96 per share price.On Jan 6, 2017, David R Guyer (Chief Executive Officer) sold 3,785 shares at 4.96 per share price.
Ophthotech Corporation (NASDAQ:OPHT) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 3 by 8 Brokerage Firm. 8 Brokerage Firms have advised hold.
Ophthotech Corporation (NASDAQ:OPHT) should head towards $9.4 per share according to 5 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $7 per share. The higher price estimate target is at $15 according to the Analysts.
Ophthotech Corporation (NASDAQ:OPHT) rose 3.14% or 0.14 points on Tuesday and made its way into the gainers of the day. After trading began at $4.45 the stock was seen hitting $4.61 as a peak level and $4.41 as the lowest level. The stock ended up at $4.6. The daily volume was measured at 762,076 shares. The 52-week high of the share price is $65.96 and the 52-week low is $4.27. The company has a market cap of $164 million.
Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.